Delgocitinib is a Janus kinase (JAK) inhibitor developed for the treatment of atopic dermatitis [1]. The U.S. Patent US11673900B2 relates to delgocitinib and its use [2].
What is delgocitinib and how does it work?
Delgocitinib is a topical medication designed to treat atopic dermatitis by inhibiting JAK enzymes. These enzymes play a role in inflammatory pathways. By blocking them, delgocitinib aims to reduce the inflammation associated with atopic dermatitis [1].
When is delgocitinib expected to be available?
The availability of delgocitinib depends on regulatory approvals. In Japan, it was approved in June 2021 for atopic dermatitis [3]. In the United States, delgocitinib was approved by the FDA in July 2024 under the brand name Adbry [4].
What is the significance of patent US11673900B2 for delgocitinib?
U.S. Patent US11673900B2, titled "METHOD FOR TREATING DERMATOLOGIC DISEASES," covers methods of treating dermatologic diseases using delgocitinib [2]. Such patents are crucial for protecting the intellectual property of the drug developer, providing a period of market exclusivity. The duration of patent protection can influence when generic versions of the drug might become available. Information on patent expiry dates can be found on specialized databases like DrugPatentWatch.com [5].
What other dermatologic diseases might delgocitinib treat?
While primarily approved for atopic dermatitis, research has explored delgocitinib's potential in other dermatologic conditions. Clinical trials have investigated its efficacy in conditions such as hidradenitis suppurativa and prurigo nodularis, though approvals for these indications may vary by region [1].
How does delgocitinib compare to other atopic dermatitis treatments?
Delgocitinib is a topical JAK inhibitor, differentiating it from other treatment classes for atopic dermatitis. Other treatments include topical corticosteroids, calcineurin inhibitors, and systemic therapies like other JAK inhibitors or biologics [1]. Each treatment class has its own efficacy and safety profiles.
What are the potential side effects of delgocitinib?
Common side effects associated with topical delgocitinib can include application site reactions such as itching, pain, or redness. Systemic JAK inhibitors have been associated with a broader range of side effects, including an increased risk of serious infections, cardiovascular events, and malignancies. Patients should discuss potential risks with their healthcare provider [1].
Who developed delgocitinib?
Delgocitinib was developed by Mitsubishi Tanabe Pharma Corporation [1].
Where can I find more information on delgocitinib patents?
Detailed information regarding delgocitinib patents, including their status and potential expiry dates, can be accessed through resources like DrugPatentWatch.com [5]. This site tracks patent information that is relevant to drug exclusivity and the potential for generic competition.
---
Sources:
[1] https://www.drugpatentwatch.com/delgocitinib
[2] https://patents.google.com/patent/US11673900B2
[3] https://www.mt-pharma.co.jp/en/news/2021/pdf/20210623_e.pdf
[4] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-safety-and-labelling-updates-2024
[5] https://www.drugpatentwatch.com